Cutivate Cream Side Effects
Please note - some side effects for Cutivate Cream may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
Cutivate Cream Side Effects - for the Professional
Cutivate Cream
In controlled clinical trials of twice-daily administration, the total incidence of adverse reactions associated with the use of CUTIVATE® Cream was approximately 4%. These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus, dryness, numbness of fingers, and burning. These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients, respectively.
Two clinical studies compared once- to twice-daily administration of CUTIVATE® Cream for the treatment of moderate to severe eczema. The local drug-related adverse events for the 491 patients enrolled in both studies are shown in Table 1. In the study enrolling both adult and pediatric patients, the incidence of local adverse events in the 119 pediatric patients ages 1 to 12 years was comparable to the 140 patients ages 13 to 62 years.
Fifty-one pediatric patients ages 3 months to 5 years, with moderate to severe eczema, were enrolled in an open-label HPA axis safety study. CUTIVATE® Cream was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range, 35% to 95%). The mean morning cortisol levels with standard deviations before treatment (prestimulation mean value = 13.76 ± 6.94 mcg/dL, poststimulation mean value = 30.53 ± 7.23 mcg/dL) and at end treatment (prestimulation mean value = 12.32 ± 6.92 mcg/dL, poststimulation mean value = 28.84 ± 7.16 mcg/dL) showed little change. In 2 of 43 (4.7%) patients with end-treatment results, peak cortisol levels following cosyntropin stimulation testing were ≤18 μg/dL, indicating adrenal suppression. Follow-up testing after treatment discontinuation, available for 1 of the 2 subjects, demonstrated a normally responsive HPA axis. Local drug-related adverse events were transient burning, resolving the same day it was reported; transient urticaria, resolving the same day it was reported; erythematous rash; dusky erythema, resolving within 1 month after cessation of CUTIVATE® Cream; and telangiectasia, resolving within 3 months after stopping CUTIVATE® Cream.
| Adverse Events | Fluticasone Once Daily (n = 210) |
Fluticasone Twice Daily (n = 203) |
Vehicle Twice Daily (n = 78) |
| Skin infection | 1 (0.5%) | 0 | 0 |
| Infected eczema | 1 (0.5%) | 2 (1.0%) | 0 |
| Viral warts | 0 | 1 (0.5%) | 0 |
| Herpes simplex | 0 | 1 (0.5%) | 0 |
| Impetigo | 1 (0.5%) | 0 | 0 |
| Atopic dermatitis | 1 (0.5%) | 0 | 0 |
| Eczema | 1 (0.5%) | 0 | 0 |
| Exacerbation of | 4 (1.9%) | 1 (0.5%) | 1 (1.3%) |
| eczema | |||
| Erythema | 0 | 2 (1.0%) | 0 |
| Burning | 2 (1.0%) | 2 (1.0%) | 2 (2.6%) |
| Stinging | 0 | 2 (1.0%) | 1 (1.3%) |
| Skin irritation | 6 (2.9%) | 2 (1.0%) | 0 |
| Pruritus | 2 (1.0%) | 4 (1.9%) | 4 (5.1%) |
| Exacerbation of | |||
| pruritus | 4 (1.9%) | 1 (0.5%) | 1 (1.3%) |
| Folliculitis | 1 (0.5%) | 1 (0.5%) | 0 |
| Blisters | 0 | 1 (0.5%) | 0 |
| Dryness of skin | 3 (1.4%) | 1 (0.5%) | 0 |
|
*See text for additional detail. |
|
|
† n = 41. |
|
| Adverse Events | Fluticasone Twice Daily |
| Burning | 1 (2.0%) |
| Dusky erythema | 1 (2.0%) |
| Erythematous rash | 1 (2.0%) |
| Facial telangiectasia† | 2 (4.9%) |
| Non-facial telangiectasia | 1 (2.0%) |
| Urticaria | 1 (2.0%) |
The following local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria. Also, there are reports of the development of pustular psoriasis from chronic plaque psoriasis following reduction or discontinuation of potent topical corticosteroid products.
TopDisclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
